Adverse reactions in connection with zimeldine treatment—a review
B. S. Nilsson
Acta Psychiatrica Scandinavica. Supplementum1983
Summary (paraphrased)
Reviewing clinical-trial and ordinary-use data from Sweden and the UK, the author reports that zimelidine's general side-effect level was substantially lower than that of tricyclic antidepressants. A hypersensitivity reaction characterized by fever, muscle and/or joint pain, and transient increases in transaminases occurred in approximately 1.5% of patients. Rare, potentially serious neuropathies were also reported in connection with treatment.
Why it’s in the corpus
verifies the hypersensitivity (~1.5%) and liver-enzyme component of zimelidine's adverse profile
Why it’s in the systems review
This is the peer-reviewed source for the hypersensitivity/liver signal the user asked to verify rather than assume. It shows the corpus's immune-related adverse-event thread for SSRIs is grounded in contemporary clinical-use data, not hindsight. Paired with MECH-046, it gives the axis a complete safety-profile picture: a frequent immune-type hypersensitivity reaction plus a rare immune-type neuropathy, matching the two immune-system-related claims the user wanted checked.